Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Parnax Lab settles...

    Parnax Lab settles case with SEBI, pays over Rs 10 lakh

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-18T11:45:58+05:30  |  Updated On 18 Nov 2018 11:45 AM IST
    Parnax Lab settles case with SEBI, pays over Rs 10 lakh

    New Delhi: Pharmaceutical company Parnax Lab has settled proceedings with markets regulator SEBI in connection with alleged violation of listing norms on payment of over Rs 10 lakh towards settlement charges.


    The order came after the company approached the Securities and Exchange Board of India (SEBI) proposing a settlement to pay a penalty without admission or denial of guilt.


    “The proposed adjudication proceedings for the alleged default ... are settled qua the applicant (Parnax Lab Ltd),” SEBI said in a settlement order dated November 9.


    It further said that SEBI will not initiate any enforcement action against the firm for the default.


    The regulator had initiated adjudicating proceedings against Parnax Lab for alleged “violation ... of Listing Agreement read ... with Securities Contracts (Regulation) Act.”


    The firm had filed an application for settlement while the adjudication proceedings were initiated by the regulator for alleged violations.


    The settlement terms proposed by the firm were considered by SEBI’s High Powered Advisory Committee (HPAC), which recommended the case for the settlement on payment of Rs 10.44 lakh. This recommendation was also accepted by the panel of whole-time members of SEBI.


    Following this, the firm paid the settlement amount and accordingly, the regulator has settled the case.


    Cressenda Solutions


    In a separate order, SEBI has imposed a fine of Rs 1.5 lakh on Cressenda Solutions for failing to comply with the markets regulator’s direction by not conducting the audit of records and systems of Sharepro Services.


    The regulator, through an order in March 2016, had asked firms, who are clients of Sharepro, to conduct a thorough audit of the records and systems of Sharepro with respect to dividends paid and transfer of securities to determine whether dividends have been paid to beneficial holders and whether securities have been transferred as per the provisions of law.


    “The notice (Cressenda Solutions) had failed to comply with the directions in the SEBI order dated March 22, 2016, by not conducting an audit of the records and systems of Sharepro,” SEBI said.

    Cressenda SolutionsHigh Powered Advisory CommitteeHPACParnax LabRs 10 lakhSEBISecurities and Exchange Board of IndiaSharepro Services

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok